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Background: Acute myocardial infarction (AMI) is the leading cause of mortality worldwide. Oxidative stress has
been involved in the ischemia-reperfusion injury in AMI. It has been suggested that reperfusion accounts for up to
50% of the final size of a myocardial infarct, a part of the damage likely to be prevented.Therefore, we propose that
antioxidant reinforcement through vitamins C and E supplementation should protect against the ischemia-reperfusion
damage, thus decreasing infarct size.
The PREVEC Trial (Prevention of reperfusion damage associated with percutaneous coronary angioplasty following
acute myocardial infarction) seeks to evaluate whether antioxidant vitamins C and E reduce infarct size in patients
subjected to percutaneous coronary angioplasty after AMI.
Methods/Design: This is a randomized, 1:1, double-blind, placebo-controlled clinical trial.
The study takes place at two centers in Chile: University of Chile Clinical Hospital and San Borja Arriarán Clinical Hospital.
The subjects will be 134 adults with acute myocardial infarction with indication for percutaneous coronary angioplasty.
This intervention is being performed as a pilot study, involving high-dose vitamin C infusion plus oral administration of
vitamin E (Vitamin-treatment group) or placebo (Control group) during the angioplasty procedure. Afterward, the
Vitamin-treatment group receives oral doses of vitamins C and E, and the Control group receives placebo for 84 days
after coronary angioplasty.
Primary outcome is infarct size, assessed by cardiac magnetic resonance (CMR), measured 6 and 84 days after coronary
angioplasty.
Secondary outcomes are ejection fraction, measured 6 and 84 days after coronary angioplasty with CMR, and biomarkers
for oxidative stress, antioxidant status, heart damage, and inflammation, which will be measured at baseline, at the onset
of reperfusion, 6 to 8 hours after revascularization, and at hospital discharge.
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Discussion: The ischemia-reperfusion event occurring during angioplasty is known to increase myocardial infarct size. The
cardioprotective benefits of high doses of vitamin C combined with vitamin E have not been fully explored. The PREVEC
Trial seeks to determine the suitability of the therapeutic use of vitamins C and E against the reperfusion damage produced
during angioplasty.
Patient recruitment opened in February 2013. The trial is scheduled to end in March 2016.
Trial registration: ISRCTN56034553
Keywords: Percutaneous coronary angioplasty, Ischemia-reperfusion, Oxidative stress, Vitamin C, Vitamin E, Acute
myocardial infarctionBackground
Primary percutaneous coronary angioplasty (PCA) is rec-
ognized as the most useful way to recover coronary flow in
the context of acute myocardial infarction (AMI). Myocar-
dial salvage and limitation of infarct-size expansion are the
principal mechanisms whereby patients with ST-segment-
elevation myocardial infarction (STEMI) benefit from
reperfusion [1]. Despite these important advances in
pharmacologic treatment and reperfusion strategies, heart
failure is a functional consequence of AMI that determines
poor long-term prognosis in coronary patients [2]. Among
others, global left ventricular function has always been
viewed as an important prognostic factor after AMI. Differ-
ent strategies have been assayed to preserve left ventricular
function and reduce infarct size in patients undergoing
primary PCA for STEMI [3,4], but no clinical benefits have
been obtained.
Currently, it is widely accepted that cardiac magnetic
resonance (CMR) imaging is the gold-standard method
to measure infarct size associated with AMI in clinical
practice [5-8] and in clinical trials [9]. CMR can also
measure accurately and reproducibly ejection fraction,
ventricular volumes and cardiac mass [5]. Infarct size has
been deemed an “important trial end-point” in the Joint
ESC/ACCF/AHA/WHF Task Force for the Redefinition of
Myocardial Infarction [10] and is a well-known outcome in
trials that evaluate amelioration of reperfusion injury,
[11-15] because its variation reflects the interaction of mul-
tiple physiologic and metabolic factors while providing a
direct measure of the amount of myocardial cell loss [16].
This direct measure is especially valuable in the context of
AMI, in which functional measures, due to the phenomena
of myocardial stunning or myocardial hibernation, may not
reflect the long-term compromise of the heart.
Reperfusion injury presents as damage to the myocar-
dium after blood restoration subsequent to a critical
period of coronary occlusion [17]. Ischemia–reperfusion
is a clinical problem associated with procedures such as
thrombolysis, angioplasty, and coronary bypass surgery,
which are commonly used to establish the blood reflow
and minimize the damage of the heart due to severe
myocardial ischemia. Reperfusion injury includes a seriesof events: (a) reperfusion arrhythmias, (b) no-reflow
phenomenon “microvascular damage, (c) myocardial stun-
ning “reversible mechanical dysfunction,” and (d) lethal
reperfusion “cell death,” which may occur either together
or separately [18,19].
Two main hypotheses, oxidative stress and Ca2+ overload,
have been proposed to explain the pathogenesis of ische-
mia–reperfusion injury [20,21]. Concerning this, oxidative
stress, which is usually associated with increased formation
of reactive oxygen species (ROS), modifies phospholipids
and proteins, leading to lipid peroxidation and oxidation of
thiol groups; these changes alter membrane permeability
and configuration and generate functional modification of
various cellular proteins [22].
Several studies have proposed the essential role of ROS
in the pathogenesis of myocardial ischemia–reperfusion
injury. In ischemic-reperfused hearts, many alterations,
such as depression in contractile function, arrhythmias,
change in gene expression, and loss of adrenergic path-
ways, have been observed [23]. Similar changes have been
reported in hearts perfused with various ROS-generating
systems. Furthermore, pretreatment of cardiac subcellular
organelles with ROS showed similar changes. Thus, alter-
ations in the myocardium during ischemia–reperfusion
were suggested to be in part due to oxidative stress. In
addition, ischemia–reperfusion was found to increase
H2O2, cytosolic free Ca
2+ concentration, malondialdehyde
(MDA) content, and the formation of conjugated dienes
in the heart. Treatment of the heart in animal models with
antioxidant enzymes, superoxide dismutase (SOD), plus
catalase protected against these changes [24,25]. ROS
seem to increase significantly after a few minutes of reper-
fusion, but the increase during ischemia alone is still
controversial.
On the basis of these changes, it has been suggested
that the increase of superoxide anion and other ROS
during reperfusion leads to lipid peroxidation and sulf-
hydryl group oxidation. It has been demonstrated that
endothelial cells, inflammatory cells (that is, neutrophils
and macrophages), and cardiomyocytes are all capable of
generating ROS through several enzymatic reactions. It
has been proposed that a burst of ROS from endothelial
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influence nearby neutrophils, setting up a local cycle of
amplified cellular response through released inflamma-
tory mediators.
Furthermore, neutrophils become sensitized (primed) to
activating factors, such as chemotactic cytokines, after
they adhere to the endothelium, and thus generate much
greater quantities of ROS. After the initial burst of ROS at
the onset of reperfusion, later events such as transen-
dothelial migration of neutrophils and macrophages,
might participate in delayed ROS generation during reper-
fusion [26,27]. Activated neutrophils produce superoxide
as a cytotoxic agent as part of the respiratory burst via the
action of membrane-bound NADPH oxidase on molecu-
lar oxygen. Neutrophils also produce the free radical nitric
oxide (NO) that can react with superoxide to produce per-
oxynitrite, the most powerful oxidant agent of nitrogen-
reactive species (NOS), which may decompose to form
hydroxyl radical [28].
In AMI, a clinical model of oxidative stress, ROS are
generated in the ischemic myocardium, especially after
reperfusion. ROS directly injure the cell membrane and
cause cell death [29]. However, ROS also stimulate signal
transduction to elaborate inflammatory cytokines(for ex-
ample, tumor necrosis factor-α (TNF-α), interleukin (IL)-
1β, and IL-6), in the ischemic region and surrounding
myocardium as a host reaction. Inflammatory cytokines
also regulate cell survival and cell death in the chain reac-
tion with ROS. Apoptosis or programmed cell death is a
distinct form of destruction of the cell, which is associated
with synthesis of enzymes that degrade and fragment its
own DNA. Updated information suggests that ischemia
followed by reperfusion significantly induces myocardial
injury by an apoptotic death pathway.
To understand the potential signaling mechanisms in-
volved in ROS-triggered apoptosis, recent reports showed
that cytosolic Ca2+overload and enhanced activity of the
mitogen-activated protein kinase (MAPK) family during
reperfusion can participate in induction of ROS-mediated
apoptosis, in addition to necrosis, and eventually could be
a determinant in infarct size [30].
Cell death was once viewed as unregulated. It is now
clear that at least a portion of cell death is a regulated cell-
suicide process. This type of death can exhibit multiple
morphologies. One of these, apoptosis, has long been rec-
ognized to be actively mediated, and many of its underlying
mechanisms have been elucidated. Moreover, necrosis, the
traditional example of unregulated cell death, is also regu-
lated in some instances. Autophagy is usually a survival
mechanism but can occur in association with increased
ROS, leading to cell death. Little is known, however, about
how autophagic cells die [31]. Apoptosis, necrosis, and
autophagy occur in cardiac myocytes during myocardial
infarction, ischemia-reperfusion, and heart failure.Pharmacologic or genetic inhibition of apoptosis and
necrosis lessens infarct size and improves cardiac func-
tion in these disorders [32].
ROS and NOS are major initiators of myocardial damage
during reperfusion. Accordingly, AMI is usually initiated
by myocardial ischemia due to coronary artery obstruction.
In the ischemic myocardium, ROS are generated by a pro-
oxidant state especially enhanced after reperfusion. Thus,
neutrophils are the primary source of ROS during reperfu-
sion. Endothelial cells and cardiomyocytes can also gener-
ate ROS. Increased ROS production is mainly due to
activation of xanthine oxidase (enzyme that catalyzes the
formation of uric acid with the co-production of super-
oxide) in endothelial cells [33], mitochondrial electron-
transport chain reactions in cardiomyocytes, and NADPH
oxidase in inflammatory cells [34]. Under these conditions,
the enzymatic antioxidant effect is relevant against the
detrimental effects of ROS. In agreement with this view, it
has been reported that the transgenic mice in which super-
oxide dismutase (SOD) is overexpressed, infarct size is
markedly reduced [35,36]. Accordingly, allopurinol, a xan
thine oxidase inhibitor, has been demonstrated to block
the superoxide production in ischemia–reperfusion set-
tings involving organs such as heart [37], liver [33], kidney
[38], and small intestine [39].
Therefore, it should be expected that a reinforcement of
the antioxidant defense system through ROS scavengers
results in a cardioprotective effect during the myocardial
reperfusion. After an ischemic episode of the myocardium,
left ventricle remodeling is known to occur; although its
underlying mechanism is multifactorial, ROS and inflam-
matory cytokines may cause a cardiodepressive reaction
[40-42]. It is of interest that ROS also stimulate the pro-
duction of inflammatory cytokines and, inversely, inflam-
matory cytokines stimulate ROS formation. In the chronic
stage, ROS and inflammatory cytokines activate the matrix
metalloproteinases [43,44], thereby eliciting degradation
of collagens, which may cause a slippage in myofibrillar
alignment, causing left ventricular dilation [45].
Major evidence exists on the contribution of ROS to
myocardial damage in AMI in humans. Therefore, it
should be expected that treatments with antioxidant agents
or upregulation of endogenous antioxidant enzymes could
protect against reperfusion injury. Some studies have sug-
gested that antioxidant agents attenuate the left ventricular
remodeling after AMI. In patients with AMI subjected to
primary percutaneous transluminal coronary angioplasty,
the pretreatment with the inhibitor of xanthine oxidase
allopurinol resulted in effective inhibition of the generation
of oxygen-derived radicals during reperfusion therapy and
the recovery of left ventricular function [46]. More
recently, the administration of edaravone, a free radical
scavenger, in patients with AMI just before reperfusion,
reduced significantly the infarct size and reperfusion
Rodrigo et al. Trials 2014, 15:192 Page 4 of 12
http://www.trialsjournal.com/content/15/1/192arrhythmia [47]. However, other attempts, such as an intra-
venous bolus of either superoxide dismutase [48] or trime-
tazidine [49], showed no beneficial effects in the outcome
of patients.
Most investigations on the health-protective effects of
vitamins C and E have been focused merely on their
antioxidant power. Nevertheless, the biologic properties
of α-tocopherol and ascorbic acid have overwhelmed
their antioxidant effects. Despite the enormous interest
in antioxidant vitamins as potential protective agents
against the development of human disease, the real contri-
butions of such compounds to health maintenance and the
mechanisms whereby they act remain unclear. Antioxi-
dants, as well as numerous cardioprotective strategies for
reducing lethal reperfusion injury, have been administered
in patients with AMI [50]. Although the scientific rationale,
epidemiologic data, and retrospective studies have been
persuasive, prospective, randomized, placebo-controlled
trials have so far failed to verify the actual benefit of anti-
oxidant vitamins in human diseases [51-54]. Among the
possible contributory factors likely to account for this dis-
crepancy,the lack of consideration of basic aspects, such as
the pharmacokinetic properties of antioxidant vitamins,
will be discussed later. In agreement with this view, previ-
ous attempts to reduce free radical production after PCA
for AMI by oral administration of vitamin C, failed to
attenuate the increased production of F2-isoprostanes [55].
In turn, Jaxa-Chamiec et al. [56], performing a random-
ized, double-blind, placebo-controlled multicentric study
in 800 patients, analyzed the effects of combined vitamins
C and E, through infusion and capsules, could not demon-
strate a major effect of this antioxidant treatment on the
clinical outcome of patients, although diabetes patients
showed a reduction in 30-day cardiac mortality [57]. It
should be noted that the authors recognize as a limitation
of the study the fact that the dose of vitamin C used in the
study increases its plasma levels only up to 0.1 mM, a con-
centration 100 times lower than that required to scavenge
superoxide anion.
Vitamin E, mainly α-tocopherol, is the major peroxyl
radical scavenger in biologic lipid phases such as mem-
branes or LDL [58,59]. The antioxidant action has been
ascribed to its ability to act chemically as a lipid-based
free radical chain-breaking molecule, thereby inhibiting
lipid peroxidation through its own conversion into an
oxidized product, α-tocopheroxyl. α-Tocopherol can be
restored by reduction of the α-tocopheroxyl radical with
redox-active reagents like vitamin C or ubiquinol [60].
In clinical studies of ischemia-reperfusion injury, positive
effects of a multivitamin antioxidant solution, including
vitamin E, were described for revascularization of the
lower extremities, kidney transplantation, liver surgery,
and aortic aneurysm repair [61-64]. Preoperative admin-
istration of vitamin E is safe, and it may have beneficialeffects by reducing the impact of ischemia-reperfusion
injury in liver surgery [65]. However, homologous stud-
ies in AMI are still lacking.
Regarding vitamin C, intraarterial administration of high
doses of ascorbate has been demonstrated to abolish the
in vivo effects of superoxide anion in the impairment of
vascular endothelial function in subjects with essential
hypertension [66]. In addition, recent in vitro studies have
also been successful to study the effects of oxidative stress
with and without this vitamin C concentration, thus
validating the use of this concentration of ascorbate to
counteract the effects of oxidative stress [66]. Vitamin C
concentration in plasma is tightly controlled, and excess of
vitamin C is excreted as a function of dose, being completely
saturated at doses of 400 mg daily and higher, producing a
steady-state plasma concentration of approximately 80 μM
[67]. Unfortunately, this concentration is not enough to
scavenge superoxide anion. Therefore, in settings accom-
panied by oxidative stress, such as the myocardial ischemia-
reperfusion cycle, a beneficial effect of oral administration of
vitamin C in the prevention of oxidative damage should not
be expected; however, intravenous infusion could be consid-
ered with this purpose. Indeed, superoxide reacts with NO
at a rate 105-fold greater than the rate at which superoxide
reacts with ascorbic acid [68]. As a consequence, 10 mM
ascorbate is needed to support its competition with NO for
superoxide. In patients undergoing elective PCA, impaired
microcirculatory reperfusion is improved by vitamin C infu-
sion, suggesting that oxidative stress is implicated in such a
phenomenon [69]. Also, in patients subjected to thromboly-
sis after AMI, superoxide dismutase in the blood was found
to be significantly reduced, whereas the activity of the oxi-
dant enzyme, xanthine oxidase, and MDA levels were found
to be significantly increased. However, oral supplementation
of vitamin C to the postreperfusion patients restored these
parameters back to normal or near-normal levels [70].
Although higher ascorbate doses would be needed to reach
a better protective effect, its biologic properties, other than
that of scavenging ROS, may have some beneficial effect.
The major source of ROS is their enzymatic production
via NADPH oxidase, an enzyme subjected to downregula-
tion by vitamin C. In addition, vitamin C prevents the oxi-
dation of tetrahydrobiopterin, a cofactor of NO synthase
that is highly sensitive to oxidation. When tetrahydrobiop-
terin is oxidized, endothelial nitric oxide synthase (eNOS)
activity becomes uncoupled, resulting in the production of
superoxide instead of NO, thus enhancing the oxidative
damage [71].
Ascorbic acid and α-tocopherol act as potent hydrophilic
and lipophilic antioxidants, respectively [72]. They also act
synergistically; in aqueous compartments, ascorbic acid
can recycle α-tocopherol in membranes by reducing
the α-tocopheroxyl radical back to α-tocopherol [73].
Consequently, in vitamin-E-supplemented rat hearts, α-
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vitamin C during reperfusion [74].
Finally, it is noteworthy that vitamin C could also
abrogate the beneficial effects of ischemic preconditioning
in animal models, a phenomenon induced by a series of
brief sublethal episodes of ischemia and reperfusion before
a potentially lethal episode of ischemia that renders the
heart more resistant to myocardial infarction [75].
Pilot study objectives
It is hypothesized that patients subjected to percutan-
eous coronary angioplasty to restore the coronary blood
flow previously impaired by an acute myocardial infarc-
tion, while receiving a short-term infusion of high doses
of vitamin C, plus oral doses of the recommended dose
of vitamin E, will have a smaller infarct size, as well as
an attenuation of the functional and biochemical damage
occurring during the reperfusion afterthe sudden loss of
blood supply, as compared with placebo-treated patients.
The objectives of this study are to determine in patients
subjected to PCA after AMI:
i. the efficacy of vitamins C and E in reducing
myocardial infarct size;
ii. the protective effects of vitamin C and E in cardiac
function, assessed by measurement of ejection
fraction;
iii. the levels of lipid peroxidation and protein
carbonylation at baseline and immediately after
successful reperfusion, 6 to 8 hours after vascular
recanalization and at discharge;
iv. the levels of antioxidant potential at baseline and
immediately after successful reperfusion, 6 to 8
hours after vascular recanalization, and at discharge;
and
v. the correlation between oxidative stress-related
biomarkers and both the infarct size and ejection




This double-blind, placebo-controlled, multicenter clinical
trial will randomize in a 1:1 ratio to either placebo-
treatment or vitamin-treatment groups. The study design
is summarized in Figure 1.
Study population
Patients of either sex, older than18 years, with an indica-
tion for primary percutaneous coronary angioplasty and
experiencing their first acute myocardial infarction, admit-
ted to University of Chile Clinical Hospital or San Borja
Arriarán Clinical Hospital, will be invited to participate inthe study. Inclusion and exclusion criteria are expressed in
Tables 1 and 2, respectively.
Recruitment of patients
Patients will be screened by a member of the research team
from those admitted to the emergency department of both
clinical centers involved in the study. Patients diagnosed
with AMI will be invited to participate in the study.
Informed consent will be obtained from suitable
patients or their representative by one of the investigators
or a delegated subinvestigator at each site. A member of
the research team will answer all questions regarding the
study and risks of the protocol procedure before the
patient signs an informed-consent form.
Sample size
Taking into account that until 50% infarct size is due to
reperfusion damage, a minimal efficacy of the interven-
tion is considered to reach a relative improvement up to
25% infarct size. Similar studies applying the same
method have provided the accuracy of measurements as
variance value. The sample size was calculated from the
following formula [76]:
n ¼ 2 ZSþ ZPð Þ2x S2= MA–MBð Þ2
Where n is the sample size for each group, “ZS” corre-
sponds to the level of significance (5%), “ZP” represents the
potency (80%), “MA” is the mean of supplemented group,
MB, the mean of the placebo group (control), and S is the
variance of CMR determination for assessment for IS. A
10% patient loss was considered for the purposes of this
calculation. This calculation rendered a sample size of 66
patients for each branch (placebo and supplemented). This
sample size is suitable to be covered by the population of
patients being treated for PCA in the Cardiovascular
Department, University of Chile Clinical Hospital, and
Cardiovascular Center, San Borja Arriarán Clinical Hospital,
during the estimated period (3 years).
Randomization and followup
Patients will be randomly allocated to one of the two
groups. The allocation sequence will be centrally gener-
ated, stored, and assigned by using online randomization
software (http://www.randomization.com) in random per-
muted blocks, each consisting of a box containing six
treatment kits allocated in a placebo-to-vitamin treatment,
1:1 ratio for each participating center.
Random allocation is generated by intervention of the
technician responsible for the treatment assignment to
recruited patients, according to the sequence already
established through the randomization method indicated
previously. The reasons for losses and exclusions after
randomization will be provided.
Figure 1 CONSORT flowchart for PREVEC Trial.
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tigators are aware of the treatment assignments. Adverse
events, unintended effects and technical problems will
be recorded.
Interventions
All patients will be asked to sign the informed consent
before beginning the protocol. For those patients allo-
cated to receive vitamin treatment, the intervention will
be started as soon as the patient has signed the informed
consent. The protocol will be started by administering
an unique oral dose of vitamin E as α-tocopherol (800IU) and an intravenous infusion of vitamin C as sodium
ascorbate (320 mM) infused at a 10-ml/min flow rate
during the initial hour and at 3 ml/min rate during the
following 2 hours. Percutaneous coronary angioplasty
will be performed about 30 minutes after initiating the
vitamin C infusion. Oral doses of vitamin E (400 IU/day)
and vitamin C (500 mg/12 hours) will be taken by the
patients for 84 days after PCA.
For those patients allocated to receive placebo treat-
ment, the 800-IU oral dose of vitamin E will be replaced
for two vegetable oil capsules (400 mg each). The intra-
venous infusion of vitamin C will be replaced by an equal
Table 1 Inclusion criteria of the study protocol
Inclusion criteria
1 Subjects may be of either sex and must be at least 18 years old
2 Subjects must have indication of primary percutaneous coronary
angioplasty (PCA):
-Angina or equivalent at least 120 minutes in duration
- Electrocardiogram with ST-segment elevation myocardial infarction
that concernsmore than two contiguous leads (>2 mm)
3 Presentation within 12 hours of symptoms onset
4 First myocardial infarction
5 Primary PCA must show a pre-PCA TIMI flow of 0
6 Subject must be able and willing to sign informed consent
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lality as the vitamin C infusion administered to supple-
mented patients. The 400-IU oral doses of vitamin E will
be replaced by vegetable oil (400 mg), and oral doses of
vitamin C will be replaced with inert starch microgranules
(500 mg). The pharmaceutical forms of vitamin C and E
are indistinguishable from their respective placebos.
After the initial evaluation, patients will go to the
catheterization laboratory. According to the standard
protocol in AMI, an angiography will be performed to
identify the infarct-related artery. The location and extent
of AMI (number of arteries involved), percentage of sten-
osis, TIMI flow, type of stent, and so on, will be recorded.
Immediately before coronary arteriography to confirm total
occlusion of one coronary artery, a basal blood sample will
be drawn from the antecubital vein. Three more blood
samples will be obtained: immediately after successful
reperfusion, at 6 to 8 hours after finishing the revasculari-
zation process and before hospital discharge.
Infarct size, the primary endpoint of the study, will be
measured with cardiac magnetic resonance (CMR) at 6
and 84 days (12 weeks) after PCA. Both determination
and data obtained by these procedures will be evaluatedTable 2 Exclusion criteria of the study protocol
Exclusion criteria
1 History of renal or hepatic insufficiency
2 History of renal lithiasis
3 History of heart failure (New York Heart Association III, IV)
4 Cardiogenic shock
5 Postprimary PCA TIMI grade flow of 0, 1, or 2
6 Any serious medical comorbidity that determines life expectancy
<6 months
7 Current participation in any other clinical investigation
8 Pregnancy
9 Glucose 6-phosphate dehydrogenase deficiencyby two independent individuals with the purpose of apply-
ing the concordance kappa index. Adherence to oral
intake of vitamins C and E or placebo will be evaluated by
telephonic contact effectuated weekly by the nurse
responsible for the trial patient´s care.
Primary and secondary outcomes
Primary outcome will be infarct size, which will be mea-
sured with CMR at 6 and 84 days (12 weeks) after PCA.
Both determination and data obtained by these proce-
dures will be evaluated by two blinded independent indi-
viduals with the purpose of applying the concordance
kappa index.
As our primary outcome is fully dependent on a high-
quality blood-flow restoration to the ischemic myocardium
region, we established as our criteria for successful reperfu-
sion only patients who have a starting TIMI flow of 0 in
the PCA and finish the procedure with TIMI flow 3,
according to the most rigorous literature standards
[77-79]. Secondary outcomes will be myocardial-damage
biomarkers, oxidative stress- and inflammation-related bio-
markers, and ejection fraction.
1. Ejection fraction: will be measured with cardiac
magnetic resonance (CMR) at 6 and 84 days
(12 weeks) after PCA. Both determination and data
obtained by these procedures will be evaluated by
two blinded independent individuals with the
purpose of applying the concordance kappa index.
2. Oxidative stress-related biomarkers:
Plasma protein carbonylation
Antioxidant capacity of plasma: Ferric
reducing ability of plasma (FRAP)
Plasma concentration of vitamins C and E
Thiol index: GSH/GSSG ratio in erythrocytes
Lipid peroxidation: F2-isoprostane and
malondialdehyde levels in plasma and
erythrocytes, respectively, will be measured.
3. Inflammation biomarkers:
High-sensitivity C-reactive protein
Leukocyte count by standard method
4. Myocardial-damage biomarkers:
Troponin, CK, and CK-MB will be
measured in plasma with standard methods
Oxidative stress- and inflammation-related biomarkers
and myocardial-damage biomarkers will be assessed
through antecubital venous blood extraction, at the
moment of enrollment (30 to 60 minutes before PCA),
immediately after successful reperfusion, at 6 to 8 hours
after finishing the revascularization process and before
discharge, as previously described. The samples will be
collected in chilled vacutainers containing disodium
EDTA (final concentration, 4 mM) and centrifuged at
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rate elements. Erythrocytes will be subjected to hypotonic
hemolysis by dilution with distilled water. Plasma and red
blood cell lysates will be stored at -80°C until performing
the biochemical analyses.
Statistical analyses
Results of continuous variables will be expressed as
mean ± standard deviation (SD). Comparison between
parametric variables will be performed by using Student
t test for unpaired samples. Nonparametric variables will
be expressed as median (interquartile range) and com-
pared through Wilcoxonrank-sum test. The significant
differences for normally distributed variables will be com-
pared with Student t test analysis of variance (ANOVA)
for repeated measures. The significant differences for non-
normally distributed variables will be compared by using
the Mann–Whitney U test. Categoric variables will be
expressed as numbers and frequencies (percentage). The
Fisher Exact test with Katz approximation will be used to
compare adverse-event frequencies.
Determination and data obtained for infarct size and
ventricular function by cardiac resonance will be evaluated
by two independent individuals with the purpose of apply-
ing the concordance kappa index. Among the limitations
of using infarct size as an outcome, is that the use of final
infarct size carries the risk of imbalances in baseline myo-
cardium at risk, according to treatment group, as well as
comparing different AMI locations, which may have
different sensitivity to the therapy [80].
In addition to this, the groups may have variable time to
reperfusion and other confounding variables that deter-
mine infarct size [81,82]. Whereas some of these difficulties
may have been corrected through a careful stratification on
entering the study, this option was discarded, given the
small sample size of this study. We are currently consider-
ing an analysis of the data though a linear regression
model, adjusted by all confounding variables, such as those
mentioned before, and others present in the current
literature [83]. P< 0.05 will be considered statistically
significant. Results will be analyzed by using Stata ver-
sion 8.0, Microsoft Excel,and Graphpad Prism 4.0.
Ethical approval of the clinical trial
The research protocol was approved by the institutional
ethics committees, including the University of Chile
Faculty of Medicine (Approval certificate 060–2011; July
19, 2011), University of Chile Clinical Hospital (Approval
certificate 53; July 27, 2011), San Borja Arriarán Clinical
Hospital (Approval certificate 468–13; July 18, 2013), and
also by the ethics committee of the National Fund for
Scientific, Technological, and Innovation Development
(FONDECYT) (Approval certificate G2-G3/590; May 24,
2012), the institution that approved the government grantsfor this clinical trial, all according to the Helsinki Declar-
ation of the World Medical Association (2000).Trial management
Patients or their representatives will be asked to sign two
copies of the informed consent. Patients will be given a
copy of their consent form to keep for reference, and the
other will be filed in the Investigator Site File on site. Data
forms will be checked for completeness and merged into a
master chart, which will be communicated to the study
statistician. Patient confidentiality will be maintained at
every stage.
Patients may withdraw from the trial or the trial treat-
ment at any time without prejudice. Patients may be with-
drawn from the study at the discretion of the local ethics
committee for safety reasons. All adverse events and
serious adverse events will be recorded during hospital
stay and through patient communication while they are
being subjected to ambulatory oral treatment. The study
coordinator will conduct meetings with the study statisti-
cian on a regular basis, and the Chief Investigator will be
made aware of all adverse events and serious adverse
events as they happen.Discussion
Given the unpredictable nature of AMI, it is not feasible
to obtain a basal myocardial image of patients; however,
this trial also does not include performing an “acute” im-
aging on admission before the PCA (again, for feasibility
reasons), but rather relies on performing a CMR on the
sixth day after AMI. In this context, it is impossible to
distinguish reperfusion damage from ischemic damage in
the same patient, based in a single “6-day after” cardiac
image. It would be expected on an imaging comparison
among groups that on the 6th and 84th days, the placebo
group exhibits, on average, a greater infarct size compared
with the supplemented group. Any significant reduction
of infarct size in the supplemented group could be attrib-
uted only to a decrease of reperfusion damage, because
full coronary ischemia would not allow the arrival of
ascorbate to the postoccluded artery segment. However, it
will be impossible to determine whether a significant
decrease of infarct size corresponds to total or partial
reduction reperfusion damage.
To the best of our knowledge, no published reports have
assessed human populations with high vitamin C levels in
AMI patients during the PCA procedure; therefore, it is
more difficult to compare data obtained with those in the
current literature. In addition, given the characteristics of
the study population, trial results are not applicable to
patients having a second AMI, III or IV Killip score AMI,
or other conditions established in the trial-exclusion
criteria. Given that this study is being performed in a
Rodrigo et al. Trials 2014, 15:192 Page 9 of 12
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nicities is uncertain.
Concerning the loss of data or patients during the
study, patients undergoing a claustrophobic reaction will
not be capable of being analyzed by CMR. Furthermore,
due to the ambulatory nature of the trial, a small loss of
patients may occur between the day 6 CMR and day 84
CMR. Given the multicentric nature of the study, the
loss of samples is possible.
To our knowledge, no previous attempts have been
made to use high doses of ascorbate to prevent or at-
tenuate the myocardial damage caused by AMI. Pharma-
cokinetic studies on vitamin C in humans have shown
that short-term infusion of high doses makes possible
the reaching of peak concentrations even higher than 20
mM, but never being below 10 mM for at least 3 hours
[84]. High doses of intravenous vitamin C have been
reported to be remarkably safe, even when administered
by infusions at a rate 3 times higher than that here
proposed [85]. Nevertheless, patients having renal im-
pairment or glucose 6-phosphate dehydrogenase defi-
ciency, known possible complications of intravenous
vitamin C, will be excluded from the present trial. How-
ever, a theoretic risk derived from high vitamin C levels
is the development of kidney stones in unreported or
first-time stone-forming patients [85].
Regarding vitamin E possible adverse effects, current
epidemiologic evidence (based on clinical trials that
tested the effect of vitamin E supplementation in healthy
participants and patients with various diseases) found
that long-term supplementation with this nutrient shows
a trend toward increasing slightly all-cause mortality
(RR, 1.03; 95% CI, 1.00 to 1.05) independent of dose and
exposition time [86]. However, the confidence interval is
barely significant, because the lower interval is 1.00. In
addition, as the Cochrane Meta-analysis explicitly
excludes tertiary prevention trials, that is, randomized
studies in which antioxidant supplements were used to
treat a specific disease, such as trials involving patients
with acute conditions (except nonmelanoma skin can-
cer), their conclusions are not applicable to our study.
Concerning the dosage, a previous meta-analysis re-
ported that high-dosage supplementations (doses ≥400
IU/d) only increase all-cause mortality with expositions
equal to or greater than 1 year [87]. Specifically in cardio-
vascular diseases, two recent meta-analysis that evaluate
the efficacy of antioxidant supplements on these patholo-
gies found no overall harmful effects in the analyzed end-
points [88,89], with the only exception of one controlled
clinical trial [90]. However, those results are not consistent
with the other related long-term large controlled clinical
trials. In any case, that study supplemented the patients
with twice our dose for more than a year, not being com-
parable in dose and timings with our study.This novel strategy, by using innocuous and easily avail-
able substances, might significantly improve the clinical
outcome of AMI patients, by reducing the infarct size,
otherwise likely to result in working disability and dimin-
ution of both their life quality and expectancy.
Given the high incidence of AMI throughout the
world and the innocuous and easily available substances
used in the study, large-scale replication of this clinical
trial worldwide seems feasible to the authors.
Trial status
The PREVEC trial began recruitment in February 2013.
Forty-three patients have been enrolled to date (3 June
2014) The trial is scheduled to end in March 2016.
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